

Ramadan Fasting and changes in thyroid function in hypothyroidism: identifying patients at risk

Short title: Ramadan Fasting and hypothyroidism control

Keywords: Ramadan, Hypothyroidism, Levothyroxine

Budour Alkaf^{1*}, MRes, Mohsin Siddiqui^{1*}, MRCP, Tomader Ali¹, PhD, Ali Bakir¹, FACP, Kevin Murphy², PhD, Karim Meeran², FRCP, Nader Lessan¹, FRCP

¹ Research Department, Imperial College London Diabetes Center, Abu Dhabi,

² Section of Endocrinology and Investigative Medicine, Imperial College London, London UK.

* Co-first authors

Budour Alkaf, balkaf@icldc.ae, +97124040800

Mohsin Siddiqui, msiddiqui@icldc.ae, +97124040800

Tomader Ali, tfali@icldc.ae, +97124040800

Ali Bakir, abakir@icldc.ae, +97124040800

Kevin Murphy, k.g.murphy@imperial.ac.uk, +44 (0)20 3313 2156

Karim Meeran, k.meeran@imperial.ac.uk, +44 (0)20 8846 1065

Nader Lessan, nlessan@icldc.ae, +97124040800

Corresponding author: Budour Alkaf

Mailing address: Imperial College London Diabetes Centre, PO Box 48338, Abu Dhabi, UAE

Telephone number: +97124040800

Fax number: +97124040983

Email address: balkaf@icldc.ae

ABSTRACT

Background

Ramadan fasting (RF) is associated with major changes in meal times. This can affect thyroxine absorption and thyroid function (TF) in patients with hypothyroidism. We aimed to examine the short and long-term impact of RF on TF in patients with primary hypothyroidism on levothyroxine.

Methods

Thyroid function tests in patients with primary hypothyroidism attending an endocrine centre in the UAE were retrospectively analysed. The impact of RF on TF, namely serum thyrotropin TSH, free thyroxine FT4 and free triiodothyronine FT3, was investigated in 481 patients within 3 months before Ramadan (BR), 1-2 weeks (PR1), and 3-6 months (PR2) post-Ramadan. Controlled TF was defined as TSH between 0.45-4.5 uIU/ml. Inadequate control was defined as TSH > 4.5 uIU/ml. Loss of control was defined as having controlled TF at BR and inadequate control at PR1. Multivariable regression analyses were used to assess the association of baseline TSH, baseline levothyroxine dose, and medication use with loss of thyroid control in Ramadan.

Results

TSH increased significantly from a median of 2.0 (0.8-3.7) uIU/ml at BR to 2.9 (1.4-5.6) uIU/ml at PR1 ($P < 0.001$). This was accompanied by a fall in FT4 and FT3 at PR1 ($P < 0.001$). 25.5% of patients with previously controlled TF at BR had deterioration in TF at PR1. 61% of patients with previously uncontrolled TF at BR remained uncontrolled at PR1. Baseline TSH was significantly associated with loss of thyroid control in Ramadan with an odds ratio (95% CI) of 1.5 (1.17,1.92) ($P < 0.001$), whereas other variables, including medications known to affect levothyroxine absorption were not associated with loss of control. TSH, FT4, and FT3 levels returned to normal at PR2.

Conclusions

RF can negatively affect TF of patients on levothyroxine replacement. Although this effect is modest and transitory in most patients, a significant minority exhibit more pronounced, and clinically relevant changes. The latter include those with higher TSH before Ramadan, and a smaller group whose thyroid disease appears to be particularly affected by the mealtime and lifestyle changes of Ramadan.

Introduction

Ramadan Fasting (RF) entails refraining from eating and drinking between dawn and sunset. It is a religious obligation widely practiced by Muslims for one lunar month a year. Although the sick are religiously exempt from the practice of RF, many choose to fast for cultural, social, personal as well as religious reasons. With the changes in meal patterns and sleeping times, physiological changes occur with RF (1-3). The long gap between main meals also dictates changes in medication timing (4). This has implications in many chronic conditions including hypothyroidism. Muslims with hypothyroidism usually opt to fast during Ramadan (5).

Levothyroxine is the standard treatment for hypothyroidism and is primarily absorbed in the small intestine, particularly through the ileum (6). Timing of levothyroxine ingestion is also known to affect its absorption (7). Based on its pharmacokinetics, the standard recommendation is that levothyroxine should be taken on an empty stomach at least 30 – 60 minutes before breakfast or three or more hours after the evening meal (usually at bedtime) (8, 9). This can be a challenge during Ramadan fasting. There is no breakfast as such during Ramadan; the equivalent is the pre-dawn meal (*suhoor*). Dinner is replaced by the sunset meal (*iftar*). It is an important social occasion and a time of intense hunger. Waking up half an hour before the planned pre-dawn *suhoor* meal for levothyroxine administration is undesirable to most patients. Similarly, at sunset, waiting thirty minutes to an hour after levothyroxine administration to eat the sunset time (*iftar*) meal would be even less practical. Therefore, ensuring good control of hypothyroidism during the month of Ramadan is both pharmacologically and practically challenging (10-12).

Although RF is widely practiced by the global Muslim population of 1.9 billion, data on the effect of RF on thyroid function are sparse, with studies investigating varied patient populations for different time periods. A few small studies have reported worsening of thyroid function tests in patients with hypothyroidism following Ramadan (13-16). Our own data of all thyroid function tests (n = 18448) performed on patients with primary hypothyroidism attending our centre during 2017 showed a modest rise in TSH and a reduction in free T4, and free T3 corresponding to Ramadan period (**Figure 1**). The primary

objective of this study was to examine the impact of RF on variations in thyroid function in a large cohort of patients with primary hypothyroidism on levothyroxine.

Materials and Methods

Serum thyrotropin (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) were measured using electrochemiluminescence immunoassay (Cobas e601 platform-Roche Diagnostics). Normal reference ranges were 0.45-4.5 uIU/ml for TSH, 10.6-22.8 pmol/l for FT4, and 3.1-6.8 pmol/l for FT3.

Figure 2 summarizes the participant flow. Data on 2435 patients who attended Imperial College London Diabetes Centre (ICLDC), United Arab Emirates (UAE) between 2012 and 2017 within 3 months before Ramadan (BR) were retrieved.

Ethics Approval and Consent

This study followed the ethical guidelines for retrospective studies, approved by the Medical Research Ethics Committee of ICLDC. Informed consent for use of clinical data in an anonymized form was obtained from patients at the time of enrolment.

Study population

Patients were included based on the following criteria (1) age ≥ 18 years; (2) Arab-Emirati; (3) diagnosed with primary hypothyroidism and on levothyroxine replacement; and (4) had thyroid function tests within 3 months before Ramadan (BR), at 1-2 weeks (PR1), and 3-6 months (PR2) post-Ramadan of the same year. Where participant's TF were available for more than one study year, only the most recent data on TF and levothyroxine dose was included in the study.

Clinician's notes on fasting during Ramadan and compliance were reviewed. Pregnancy status for women at the three time-points was extracted. Although trimester specific thyroid function ranges in UAE pregnant women on Cobas e601 platform have been previously reported in 2018 (17), these were not implemented in the centre during the study period. Hence, the same assay specific ranges have been used in pregnant women as in the non-pregnant population.

Prescribing information on levothyroxine dose and drugs that may affect levothyroxine absorption, such as proton pump inhibitors, iron and calcium supplements, were also retrieved. Mean daily dose was calculated by averaging the total dose over the week. The standard recommendation for timing of levothyroxine during Ramadan by ICLDC physicians is to take it late at night, unless half an hour before *iftar* is practical.

Exclusion criteria

Patients with type 1 diabetes (T1DM) were excluded as they are often advised not to fast during Ramadan. Patients were also excluded if they had secondary(central) hypothyroidism or subclinical hypothyroidism.

Statistical analysis

Statistical analyses were performed using GraphPad Prism version 8 (GraphPad Software, La Jolla California USA) and SPSS version 25 (IBM Corp., Armonk, NY, USA). Values are presented as means with standard deviations (SD) and medians with interquartile range (IQRs). The normality of parameters studied was tested using the Shapiro-Wilk test. Non-parametric paired sample tests (Wilcoxon) were used to test for differences in TSH, FT4, and FT3 values before Ramadan (BR) compared to each time point post-Ramadan (PR1 and PR2). Sensitivity analyses were performed to assess the confounding effect of pregnancy on TF. Controlled TF was defined as TSH between 0.45-4.5 uIU/ml and inadequate control was defined as TSH > 4.5 uIU/ml. Loss of control was defined as having controlled TF at BR and inadequate control at PR1. Multivariable regression analyses were used to evaluate any potential association of age, gender, TSH and FT4 at BR, levothyroxine dose at BR, and medication use with loss of thyroid control in Ramadan.

Results

Study population and baseline characteristics have been summarized in Table 1. 481 patients with full thyroid function tests before (BR) and after (PR1 and PR2) Ramadan were included in the study. Mean (SD) age was 44.0 (12.7) years and mean (SD) body mass index (BMI) was 30.0 (6.0) kg/m². 89.9% were females, of which 14.4% (n = 62) were pregnant during the study. The most frequent cause of primary hypothyroidism in the study

population was chronic (autoimmune) thyroiditis (88.4%). 16 patients (3.3%) had history of thyroid carcinoma and underwent total thyroidectomy and radioiodine ablation. 47 patients (10% had type 2 diabetes (T2DM).

TSH increased within two weeks post-Ramadan (PR1), from a median (IQR) of 2.0 (0.8-3.7) uIU/ml at BR to 2.9 (1.4-5.6) uIU/ml at PR1 ($P < 0.001$) (Figure 3A). This was accompanied by a drop in FT4 and FT3, from 16.9 (14.6-19.3) pmol/l and 4.2 (3.9-4.6) pmol/l at BR, to 16.1(14.2-18.5) pmol/l and 4.0 (3.7-4.5) pmol/l at PR1, respectively ($P < 0.001$) (Figure 3B and C). At 3-6 months post-Ramadan (PR2), TSH levels dropped to a median (IQR) of 1.6 (0.5-3.0) uIU/ml. This was accompanied by a rise in FT4 and FT3 levels at PR2 to a median (IQR) of 17.1 (15.0-19.8) pmol/l and 4.2 (3.9-4.7) pmol/l (Figure 3). Sensitivity analyses did not reveal an effect of pregnancy on these observations (**Figure 4**). In addition, similar results were also observed in a subgroup analysis of non-pregnant premenopausal and menopausal women, with significantly higher TSH at PR1 compared to BR in both groups (Supplementary table 1). In men, however, no significant changes were observed (Supplementary table 1).

In 80 patients with previously normal TF, there was a rise in TSH to above normal range within 2 weeks after Ramadan (PR1). This constituted 16.6% of the total cohort and 5.4% of patients with previously good control at BR ($n = 314$). Out of these, 52 participants had a rise in TSH above 10.0 uIU/ml. Total number of patients with TSH above normal range at BR was 93 (19.3%); 61% of this group ($n = 57$) remained inadequately controlled with TSH remaining above 4.5 mIU/l at PR1 (**Supplementary figure 1**). Out of the 481 patients, 306 (63.6%) did not have any changes in their levothyroxine dose throughout the study period. TSH levels in this subgroup ($n = 306$) increased significantly from a median (IQR) of 1.8 (0.8-2.8) to 2.6 (1.3-4.5) ($P < 0.001$). 109 patients had a change in levothyroxine dose on review at BR; 83 patients of these had dose up titration (Supplementary figure 1). In this subgroup ($n = 109$), increase in TSH levels post Ramadan was not significant (median (IQR) at BR 3.6 (0.8-7.13) versus 3.8 (1.7-6.9) at PR1, $P = 0.371$). There were no significant changes in weight, BMI or lipid profile between BR and PR1 (Supplementary table 2). The changes remained insignificant in the subgroup who were euthyroid before Ramadan and lost control during Ramadan (EH).

Baseline TSH was significantly associated with loss of thyroid control in Ramadan with an odds ratio (95% CI) of 1.5 (1.17,1.92) ($P<0.001$) (Table 2). In a subset of patients who were euthyroid at BR ($n = 314$), this association remained significant (odds ratio 1.5, $P = 0.001$). However, age, gender, FT4 at BR, medications known to affect levothyroxine absorption were not associated with loss of control.

Discussion

This study demonstrates important alterations in thyroid function in Ramadan-fasting adults with primary hypothyroidism on levothyroxine replacement and explores factors that could explain these observations.

Our findings are consistent with other studies that have reported worsening of TF in hypothyroid patients following Ramadan (10-15). There is only one published study on the effect of RF on thyroid function in healthy adults ($n=41$) (13), which reported a significant gradual rise in TSH throughout the fasting month, but no significant change in FT4 and FT3 levels (13). Karoli et al observed a mean TSH rise > 2 mIU/l in 60% of euthyroid patients ($n = 47$), who were instructed to take levothyroxine at bedtime, at least 2 hours after the last meal (14). A prospective cohort study in 64 individuals with primary hypothyroidism showed similar results with the mean rise in TSH of 2.32 ± 3.80 mIU/l after Ramadan. The change in TSH was not affected by the timing of levothyroxine administration and time interval from the meal (10). Another prospective study on 36 Iranian hypothyroid women reported a significant drop in FT4 and a non-significant rise in TSH during Ramadan (15).

Interaction with interfering drugs and food, decreased compliance or physiological effects of RF on thyroid hormone secretion were considered. In our cohort, potentially interfering drugs do not appear to be a significant factor in affecting thyroid functions during Ramadan.

Drug compliance during Ramadan takes a different form from non-fasting days as concordance with medications is frequently compromised during Ramadan. In a study comparing levothyroxine intake in two groups, 30 minutes before *iftar* and 30 minutes before *suhoor*, patients in both groups found both regimens challenging and compliance to administration timing was only 30 to 35% (16). In a recent randomized controlled trial by

El-Kaissi et al comparing three different groups who were instructed to take levothyroxine at a designated time; 30 minutes before *iftar*, ≥ 3 hours after *iftar* and 30 minutes before *suhoor*, participant compliance was only between 59.3% to 77.1% (18). Although the authors reported that the levothyroxine intake 30 minutes before *iftar* meal minimizes the TSH excursions post-Ramadan, the patient satisfaction of this intake time was moderate and the likelihood of patient concordance in routine practice is expected to be even lower. However, it is noteworthy that there was an unexplained discrepancy in the compliance and satisfaction rates amongst their patients; although the group taking levothyroxine in *suhoor* was most dissatisfied with that time, they remained the most compliant of the three groups. The standard recommendation by ICLDC physicians to patients for the timing of levothyroxine intake during Ramadan has been at bedtime a few hours after the *iftar* meal as it appears to be more practical and preferable for most patients.

Our data demonstrate that 60% of patients with previously inadequate control before Ramadan remain inadequately controlled with TSH above 4.5 mIU/l post-Ramadan (Supplementary figure 1). However, the effect of Ramadan fasting on changes in TSH in this subgroup in the absence of non-fasting controls remains unclear and requires further exploration in a prospective design with a comparison group. Interestingly, approximately 25% of patients who were previously euthyroid lost control during Ramadan (Supplementary figure 1). As such, the current study identifies the less well-controlled group before Ramadan as a target group for a focused pre-Ramadan education. It is likely that these represent people with inadequate drug compliance and those with more recently diagnosed hypothyroidism. Compliance issues can also be exacerbated by the time constraints of Ramadan. In the UAE for instance, as Ramadan was in the summer months between 2012 and 2017, a typical fasting day would last for approximately 14 hours (19)(17). Hence, Muslims were only able to eat or drink for a few hours after sunset. The interaction of food with levothyroxine could have reduced its absorption.

In a secondary multivariable regression analysis, only baseline TSH was a predictor for loss of control during Ramadan, whereas age, gender, baseline FT4, levothyroxine dose and interfering medications were not found to affect thyroid control in our cohort. This is in contrast to recent work from El-Kaissi et al who suggested that males and older adults are

more prone to loss of control post-Ramadan (20). However, as also acknowledged by the authors, this retrospective study included only 10 male participants and yielded statistically insignificant results. The more recent prospective work from the same investigators didn't demonstrate the effect of age or gender on Ramadan related TSH elevation (18). Our study benefits from a higher number of male participants ($n = 49$) and did not find that they are at higher risk of loss of control during Ramadan. Premenopausal women are exempted from fasting during their menstrual periods; our analysis showed a more notable and significant rise in TSH in this subgroup. Hence, the abstinence from fasting for a few days during menstruation doesn't appear to diminish the changes in TSH observed.

Therapeutically, small increases in levothyroxine dose by 25 to 50 ug/day from the beginning of Ramadan till 2 to 3 weeks post-Ramadan have been previously suggested to improve the control of hypothyroidism (11-16). However, the effect of this small increase in levothyroxine dose or the timing of its administration during Ramadan has not been evaluated in a prospective trial. Our data suggest that this postulated dose increase can be considered for individuals with TSH at the upper end of the normal range before Ramadan and not necessarily in all patients.

There did not appear to be any significant changes in weight, BMI or lipid profile in patients during Ramadan. Since the observed TSH changes are relatively minor in most patients, the magnitude of their effect on lipids is unlikely to be significant. In addition, concomitant lipid lowering therapy could be an important confounding factor in these patients.

Based on our study findings, we suggest clinicians take into consideration the possibility that a patient may have just completed a period of fasting, and that physicians may need to be cautious in making any dose adjustments in the early period after Ramadan. However, this should not discourage physicians from assessing thyroid function after Ramadan if clinically warranted.

Potential limitations of our study include selection bias and its retrospective design. The latter has allowed us to look at changes in a relatively large number of patients with

hypothyroidism in the context of Ramadan fasting and in a “real world” setting. In this study, we deliberately chose patients who had thyroid function data at all three time points of interest, and as such, the study may have been subject to some selection bias. In addition, the retrospective design of the study meant it was not possible to confirm whether the subjects included in the study fasted during the entire month of Ramadan in the study year. However, studies during Ramadan in the Middle East, including those on patients with diabetes for instance (21, 22) and our own experience in Emirati individuals with Type 1 and Type 2 diabetes in a prospective study has shown that at least 80% of these choose to fast most of Ramadan (unpublished data). Hence, extrapolating from Diabetes and Research alliance (16) surveys conducted in high-risk patients, it will be safe to assume that patients with thyroid disorders are even more likely to fast during Ramadan. Since RF is so commonly practiced amongst the Emirati population even with multiple comorbidities, whether a patient practiced RF was not specifically documented in clinic consultations post-Ramadan (PR1). Another limitation is that the levothyroxine administration timing during Ramadan and its relation to meals was not available in the patient records. Changes in levothyroxine dose may warrant more frequent visits. However, only a quarter of the total cohort in our study had a dose change at BR, and thus it is unlikely that this was a major contributing factor for repeat thyroid functions post-Ramadan. Moreover, coexisting conditions such as malabsorption syndromes, autonomic neuropathy from diabetes or previous bariatric surgery may influence the levothyroxine absorption but the number of people with these comorbidities was small, and as such the overall effect on TF is likely to be minor.

Conclusions

In conclusion, we have demonstrated that RF is associated with a statistically significant rise in TSH in patients on levothyroxine treatment. However, the magnitude of the observed change in TSH in our study is not of clinical significance at a population level. In a multivariable analysis, we observed that a small group of patients with higher TSH are potentially at an increased risk for loss of TF control during Ramadan. Healthcare professionals should consider discussing the potential implications of RF on TF control with levothyroxine-treated patients, with special attention to those whose TF are already

inadequately controlled. Prospective studies are needed to evaluate the clinical significance of these changes. Such studies will have the advantage of specific information on the actual timing of levothyroxine ingestion and the number of days fasted by the participants. A tailored levothyroxine dose increase may be considered in some patients. Future studies will also need to explore any associated changes in physiological processes and the hypothalamo-pituitary-thyroid axis, which may impact TF control during Ramadan fasting.

Acknowledgements

We are grateful to Miss Alia Al Tikriti and Magdaa Fukaha for their help with data extraction and their assistance in the study.

Author contribution statement(s)

Budour Alkaf and Mohsin Siddiqui should be considered as co-first authors.

Budour Alkaf was involved in statistical analysis of the data presented and writing methods and results sections.

Mohsin Siddiqui contributed to data interpretation and drafting the introduction and discussion sections of the manuscript.

Tomader Ali reviewed the data and contributed to drafting the manuscript.

Ali Bakir contributed to conceptualizing the study and reviewing the work.

Kevin Murphy reviewed the work and edited the manuscript.

Karim Meeran reviewed the work and edited the manuscript.

Nader Lessan contributed to conceptualizing the study, writing and editing the manuscript and reviewing data analysis and presentation.

Author disclosure statement(s)

Budour Alkaf has no conflicts to disclose.

Mohsin Siddiqui has no conflicts to disclose.

Tomader Ali has no conflicts to disclose.

Ali Bakir has no conflicts to disclose.

Kevin Murphy has no conflicts to disclose.

Karim Meeran has no conflicts to disclose.

Nader Lessan has no conflicts to disclose.

Funding statement(s)

There is no funding to declare for this study.

References

1. Leiper JB, Molla AM, Molla AM 2003 Effects on health of fluid restriction during fasting in Ramadan. *Eur J Clin Nutr* 57:S30-S38.
2. Lessan N, Ali T 2019 Energy Metabolism and Intermittent Fasting: The Ramadan Perspective. *Nutrients* 11.
3. Roky R, Houti I, Moussamih S, Qotbi S, Aadil N 2004 Physiological and chronobiological changes during Ramadan intermittent fasting. *Ann Nutr Metab* 48:296-303.
4. Aadil N, Houti IE, Moussamih S 2004 Drug intake during Ramadan. *BMJ* 329:778-782.
5. Azizi F 2015 Islamic Fasting and Thyroid Hormones. *Int J Endocrinol Metab* 13:e29248.
6. Hays MT 1988 Thyroid hormone and the gut. *Endocr Res* 14:203-224.
7. Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J 2009 Timing of levothyroxine administration affects serum thyrotropin concentration. *J Clin Endocrinol Metab* 94:3905-3912.
8. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM 2014 Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. *Thyroid* 24:1670-1751.
9. Parretti H, Okosieme O, Vanderpump M 2016 Current recommendations in the management of hypothyroidism: developed from a statement by the British Thyroid Association Executive. *Br J Gen Pract* 66:538-540.
10. Sheikh A, Mawani M, Mahar SA 2018 IMPACT OF RAMADAN FASTING ON THYROID STATUS AND QUALITY OF LIFE IN PATIENTS WITH PRIMARY HYPOTHYROIDISM: A PROSPECTIVE COHORT STUDY FROM KARACHI, PAKISTAN. *Endocr Pract* 24:882-888.

11. Or Koca A, Dağdeviren M, Altay M 2020 Should the dose of levothyroxine be changed in hypothyroidism patients fasting during Ramadan? Turk J Med Sci 50:784-788.
12. Zaboon IA, Alidrisi HA, Hussein IH, Alabbood M, Alibrahim NTY, Almomin AMS, Al-Waeli DK, Alhamza AHA, Mohammed AG, Nwayyir HA, Al-Ali AJH, Mansour AA 2020 Best Time for Levothyroxine Intake in Ramadan (THYRAM): Basrah Experience. Int J Endocrinol Metab 18:e94325-e94325.
13. Sajid KM, Akhtar M, Malik GQ 1991 Ramadan fasting and thyroid hormone profile. J Pak Med Assoc 41:213-216.
14. Karoli R, Fatima J, Chandra A, Mishra P 2013 Levothyroxine replacement and Ramadan fasting. Indian J of Endocrinol Metab 17:318-319.
15. Pakdel R, Mohebbi M, Rezaie N, Hadjzadeh M-A-R 2020 Ramadan Fasting and Thyroid Hormone Levels in Women with Hypothyroidism. J of Nutr Fast Health 8:55-60.
16. Dabbous Z, Alowainati B, Darwish S, Ali H, Farook S, Al Malaheem M, Abdalrubb A, Gul W, Haliqa WA 2019 A Prospective Study Comparing Two-Time Points of Thyroid Hormone Replacement during the Holy Month of Ramadan. Int J of Endocrinol 2019:9843961.
17. Khalil AB, Salih BT, Chinengo O, Bardies MRD, Turner A, Abdel Wareth LO 2018 Trimester specific reference ranges for serum TSH and Free T4 among United Arab Emirates pregnant women. Pract Lab Med 12:e00098.
18. El-Kaissi S, AbdelWareth L, Dajani R, Lee-St John TJ, Santarina SA, Makia F, AlTahruri M, Kaskas A, Ahmed Y 2021 Levothyroxine Administration during Ramadan: A Prospective Randomized Controlled Trial. Eur Thyroid J 10:455-460.
19. Time and Date. Abu Dhabi, Abu Dhabi, United Arab Emirates — sunrise, sunset, and daylength, 2021. <https://www.timeanddate.com/sun/United-Arab-Emirates/Abu-Dhabi?month=1>.

20. El-Kaissi S, Dajani R, Lee-St. John TJ, Ann Santarina S, Makia F, ALTakruri M, Ahmed Y 2020 Impact of Lifestyle Changes During Ramadan on Thyroid Function Tests in Hypothyroid Patients Taking Levothyroxine. *Endoc Pract* 26:748-753.
21. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, Hanif W, Lessan N, Basit A, Tayeb K, Omar M, Abdallah K, Al Twaim A, Buyukbese MA, El-Sayed AA, Ben-Nakhi A 2017 Diabetes and Ramadan: Practical guidelines. *Diabetes Res Clin Pract* 126:303-316.
22. Hassanein M, Hussein Z, Shaltout I, Wan Seman WJ, Tong CV, Mohd Noor N, Buyukbese MA, El Tony L, Shaker GM, Alamoudi RM, Hafidh K, Fariduddin M, Batais MA, Shaikh S, Malek PR, Alabboud M, Sahay R, Alshenqete AM, Yakoob Ahmedani M 2021 The DAR 2020 Global survey: Ramadan fasting during COVID 19 pandemic and the impact of older age on fasting among adults with Type 2 diabetes. *Diabetes Res Clin Pract* 173:108674.

Table 1. Basic characteristics of population studied at before Ramadan time point (BR).

	N = 481
Age (years)	
Mean (SD)	44.0 (12.7)
Median (IQR)	42.0 (35.0-52.0)
Sex n (%)	
Female	432 (89.8)
Male	49 (10.2)
Indication for levothyroxine n (%)	
Chronic (autoimmune) thyroiditis	422 (88.4)
Post surgical	25 (5.2)
Total thyroidectomy and radioiodine ablation for thyroid carcinoma	16 (3.3)
Radioiodine ablation	8 (1.6)
Postpartum thyroiditis	6 (1.2)
Pregnancy n (%)	
Pregnant women	62 (14.4)
Diabetes n (%)	
NGT	271 (56.3)

Pre-diabetes	149 (31.0)
T2DM	47(9.8)
BMI (kg/m2)	
Mean (SD)	30.0 (6.0)
Median (IQR)	29.4 (25.7-33.3)
Lipid Profile	
TC (mmol/l)	
Mean (SD)	4.7(0.9)
Median (IQR)	4.7 (4.1-5.3)
LDL (mmol/l)	
Mean (SD)	3.1 (0.8)
Median (IQR)	3.0 (2.5-3.6)
HDL (mmol/l)	
Mean (SD)	1.4 (0.4)
Median (IQR)	1.4 (1.2-1.7)
Triglycerides (mmol/l)	
Mean (SD)	1.2 (0.6)
Median (IQR)	1.1 (0.8-1.5)
Thyroid function	
TSH (μIU/ml)	

Mean (SD)	3.7 (9.2)
Median (IQR)	2.0 (0.8-3.7)
FT4 (pmol/l)	
Mean (SD)	17.1 (4.1)
Median (IQR)	16.9 (14.6-19.3)
FT3 (pmol/l)	
Mean (SD)	4.3 (0.8)
Median (IQR)	4.2 (3.9-4.6)
Levothyroxine dose (mg)	
Mean (SD)	85.57 (42.4)
Median (IQR)	78.57 (50-100)
Interfering medications n (%)	
Iron supplements	55 (11.4%)
Calcium supplements	45 (9.4%)
Proton pump inhibitors	34 (7.1%)

Data are shown as n (%) or mean (SD) and median (interquartile range).

Abbreviations: NGT, normal glucose tolerance, T2DM, type 2 diabetes, BMI, body mass index, TC, total cholesterol, LDL, low-density lipoprotein, HDL high-density lipoprotein.

Table 2. Multivariable logistic regression analysis to assess the association of baseline TSH, LT4 dose, and FT4 with risk of loss of thyroid control in Ramadan. 481 patients with primary hypothyroidism and on levothyroxine who attended at BR (2-3 months before Ramadan), PR1 (1-2 weeks post Ramadan), and PR2 (3-6 months post Ramadan) were selected.		
Covariates	OR (95%CI)	P
BR TSH		
Unadjusted	1.5 (1.17,1.91)	0.001
Adjusted †	1.5 (1.17,1.92)	0.001
BR FT4		
Unadjusted	1.06 (0.97,1.15)	0.192
Adjusted †	1.06 (0.97,1.15)	0.207
BR LT4 dose		
Unadjusted	1.0051 (0.9971,1.0131)	0.209
Adjusted †	1.006 (0.9979,1.0142)	0.147
Interfering medications		
Unadjusted	1.13 (0.61,2.07)	0.701
Adjusted †	1.13 (0.60,2.13)	0.710

† Adjusted for age and BMI at baseline (2-3 months before Ramadan)




Figure 1. Monthly Changes in Thyroid Function in Patients with Treated Primary Hypothyroidism Throughout a Full Year.

Line graphs demonstrating monthly changes in median (A) TSH, (B) FT4, and (C) FT3 levels of 18,448 thyroid function tests performed in patients with treated primary hypothyroidism throughout 2017. The 12 months (January—December) are labelled in the x-axis. The error bars represent the interquartile range. In 2017, the month of Ramadan started on the 26th of May and ended on the 24th of June. For each month (January–December), the number of thyroid function tests (n) were indicated.




Figure 2. Participant Flow

Flowchart demonstrating data retrieval and processing used to investigate the short-term (1-2 weeks; PR1) and long-term (3-6 months; PR2) impact of Ramadan Fasting on hypothyroidism control in 481 patients with treated primary hypothyroidism.




Figure 3. Effect of Ramadan Fasting on TSH, FT3 and FT4 levels in Patients with Primary Hypothyroidism.

Box plots demonstrating levels (A) TSH, (B) FT4, and (C) FT3, at 2-3 months Before-Ramadan (BR), 1-2 weeks (PR1), and 3-6 months post-Ramadan (PR2). 481 patients with primary hypothyroidism and on levothyroxine were selected and followed up at PR1 and PR2. (*) indicates statistical significance at $p \leq 0.05$, (**) indicates statistical significance at $p < 0.01$, (***) indicates statistical significance at $p < 0.001$.




Figure 4. Sensitivity analysis - Effect of Ramadan Fasting on TSH, FT3 and FT4 levels in Patients with Primary Hypothyroidism.

Box plots demonstrating levels (A) TSH, (B) FT4, and (C) FT3, at 2-3 months Before-Ramadan (BR), 1-2 weeks (PR1), and 3-6 months post-Ramadan (PR2). 419 patients with primary hypothyroidism and on levothyroxine were selected and followed up at PR1 and PR2. Data presented excludes 62 women who were pregnant at BR and/or PR1. (*) indicates statistical significance at $p \leq 0.05$, (**) indicates statistical significance at $p < 0.01$, (***) indicates statistical significance at $p < 0.001$.